Compare InMode Ltd (INMD) vs Teradyne, Inc. (TER) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
InMode Ltd vs Teradyne, Inc. — how do they compare? InMode Ltd trades at $14.07 (market cap $806.05M), while Teradyne, Inc. trades at $408.01 (market cap $64.38B). The key difference: Teradyne, Inc. is far larger — about 79.9× InMode Ltd's market cap, and Teradyne, Inc. pays a 0.13% dividend while InMode Ltd pays none. Which is the better fit depends on your goals — on Pluang, investors hold InMode Ltd for 29 Days and Teradyne, Inc. for 37 Days on average.
| INMD | TER | |
|---|---|---|
Market Cap | $806.05M | $64.38B |
Volume | 511,446 | 2,394,954 |
Sector | Health | Technology |
52-Week High | $16.62 | $483.84 |
52-Week Low | $12.76 | $132.05 |
Typical Hold Time | 29 Days | 37 Days |
Enterprise Value | $309.39M | $64.12B |
Dividend Yield | — | 0.13% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
INMD trades at $14.01, showing minimal daily movement with a 0.14% gain. The stock faces bearish technical signals despite attractive valuation metrics including a P/E of 11.58 and EV/EBITDA of 4.43. Recent earnings show mixed results with Q2 2026 beating expectations but Q1 2026 missing, while the company faces shareholder activism from Steel Partners' $16.75 per share acquisition offer. Revenue guidance for 2026 remains stable at $365M-$375M.
The investment case balances strong profitability margins against technical weakness and activist pressure. With 45% analyst buy ratings and no sell recommendations, fundamental value appears intact, but near-term price action suggests caution. Key catalysts include Q3 2026 earnings and resolution of the acquisition proposal, while risks include execution challenges and macroeconomic headwinds affecting aesthetic medicine demand.
Teradyne (TER) trades at $398.72, down 7.34% over 24 hours, but maintains strong technical support near $399. The company demonstrates robust fundamentals with consistent earnings beats (Q4 2025-Q2 2026) and expanding AI-driven test portfolio through new products like Magnum E2 and Iris 100. Revenue growth is projected to accelerate from $3.19B in 2025 to $4.5B in 2026, with net income margin improving to 25.76%.
Outlook remains positive with 61% analyst buy ratings and $461.50 consensus price target, representing 16% upside. Key risks include semiconductor cycle volatility and competitive pressure from KLAC & COHU. Institutional accumulation continues with recent purchases by Envestnet and Nykredit, supporting bullish sentiment despite insider selling.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
No sentiment data available yet.
About InMode Ltd
InMode provides innovative medical technologies for minimally invasive surgical procedures. Its platforms use radiofrequency (RF) energy for aesthetic treatments like body contouring and skin tightening.
Read more on INMD →About Teradyne, Inc.
Teradyne provides testing equipment, including automated test equipment for semiconductors, system testing for hard disk drives, circuit boards, and electronics systems and wireless testing for devices. The firm entered the industrial automation market in 2015, into which it sells collaborative and autonomous robots for factory applications. Teradyne serves numerous end markets and geographies directly and indirectly with its products, but its most significant exposure is to semiconductor testing, which made up 71% of 2021 sales. Teradyne serves vertically integrated, fabless, and foundry chipmakers with its equipment.
Read more on TER →
